-transparent.png){kind=logo}
In a report of two patients who died of malignant hyperthermia, muscle adenylate kinase deficiency was identified in the father and brother of the deceased. To determine if this enzyme deficiency was a biochemical marker for susceptibility to malignant hyperthermia, we measured adenylate kinase in muscle of three survivors of malignant hyperthermia (MH) and five relatives of survivors of MH attacks with positive caffeine contracture tests. Neither the activity nor the electrophoretic mobility of adenylate kinase differed from four control values. The results show that muscle adenylate kinase deficiency is not a biochemical abnormality shared by all individuals susceptible to malignant hyperthermia.
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
January 1974,
Humangenetik,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
April 1988,
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
February 1969,
Lancet (London, England),
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
September 1982,
British journal of anaesthesia,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
June 1970,
La Presse medicale,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
March 1989,
Muscle & nerve,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
August 1981,
Masui. The Japanese journal of anesthesiology,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
June 1984,
Anesthesiology,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
May 1993,
Muscle & nerve,
C G Cerri, and
J H Willner, and
B A Britt, and
D S Wood
June 1996,
Proceedings of the National Academy of Sciences of the United States of America,
